Calidi Biotherapeutics (CLDI): Director received 5,000 units
James A Schoeneck, Director at Calidi Biotherapeutics, reported a grant / award of 5,000 units.
- 5,000
- Derivative units
- Traded
- Aug 17, 2026
- Filed
- Aug 19, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 17, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On June 17, 2026, the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee appointed Dr. Corazon (Corsee) Sanders to serve as a Class III director of the Company, with a term expiring at the Company’s 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier…”
- Jul 10, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
- Jul 27, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year
- Aug 13, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
What came next
- Sep 17, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
- Sep 21, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On September 21, 2026, Calidi Biotherapeutics, Inc. (the “Company”) received a letter (the “Notice”) from staff of NYSE American LLC (the “Exchange”). The Notice stated that the Company is not in compliance with the stockholders’ equity continued listing standard in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”).”
- Nov 13, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Calidi Biotherapeutics
OQRO holds no insider, Congress, fund or contract record for Calidi Biotherapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLDI page.
Other recent filings by James A Schoeneck, Director
- SEC Form 4 at Calidi Biotherapeutics (CLDI)Aug 26, 2025
- SEC Form 4 at Kyntra Bio (KYNB)Jul 2, 2025
- SEC Form 4 at Kyntra Bio (KYNB)Mar 24, 2025
- SEC Form 4 at Kyntra Bio (KYNB)Mar 24, 2025
The full history of James A Schoeneck, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Calidi Biotherapeutics (CLDI) insider traded, and how much?
James A Schoeneck, Director at Calidi Biotherapeutics, reported a grant / award of 5,000 units. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Aug 17, 2026. Filed: Aug 19, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean CLDI stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Calidi Biotherapeutics
- SEC Form 4Dec 17, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Aug 26, 2025
- SEC Form 4Dec 19, 2024
Everything OQRO holds on this company is on its CLDI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
